Welcome to our dedicated page for 3D Systems news (Ticker: DDD), a resource for investors and traders seeking the latest updates and insights on 3D Systems stock.
3D Systems Corporation develops additive manufacturing and digital manufacturing solutions built around 3D printers, materials, software and application engineering services. Its news commonly covers production systems for polymers and metals, NextDent dental printing and materials, SLA technology, factory software such as AddiTrak, and customer deployments in medical, dental, aerospace, defense, transportation, motorsports and industrial markets.
Company updates also include financial results, cost and efficiency programs, leadership changes, regulatory certifications for dental products, and commercial adoption of healthcare and industrial applications. These developments reflect the company’s focus on full-service solutions that combine hardware, materials, software and manufacturing expertise.
3D Systems (NYSE: DDD) announced that Charles (Chuck) Hull, co-founder and chief technology officer for regenerative medicine, has been elected to the National Academy of Engineering (NAE). Hull, who invented 3D printing and pioneered Stereolithography (SLA), created the first 3D-printed part in 1983 and co-founded 3D Systems in 1986.
Hull's achievements include receiving the National Medal of Technology and Innovation from President Biden in 2023, induction into the National Inventors Hall of Fame (2014), and the European Inventor Award (2014). He holds 85 US patents and numerous international patents in ion optics and 3D printing. His invention of SLA launched the commercial 3D printing industry with the first printer, the SLA-1.
Hull will be formally inducted during the NAE's Annual Meeting on October 5, 2025, along with 128 new members and 22 international members in the Class of 2025.
Systemic Bio, a 3D Systems (NYSE: DDD) company, has won the prestigious SLAS 2025 Innovation Award for its groundbreaking technological advancements in laboratory science. The award recognizes the company's proprietary h-VIOS™ platform, which accelerates drug discovery using bioprinted human tissues.
The company's winning presentation demonstrated the platform's ability to evaluate antibody-drug conjugates (ADCs) safety, identifying risks typically only discovered during clinical trials. Operating from Houston, Texas, Systemic Bio maintains an ISO 7 clean room and Quality Management System, enabling the production of thousands of tissue models.
CEO Taci Pereira emphasized the award's significance as validation of their platform's scientific value. The company continues collaborating with leading pharmaceutical companies to enhance preclinical drug testing and reduce late-stage failures through their innovative technology.
3D Systems (NYSE: DDD) and Daimler Truck | Daimler Buses have announced a groundbreaking solution for remote spare part printing. The collaboration, which includes Oqton and Wibu-Systems, enables Daimler Buses' certified partners to produce spare parts locally while protecting intellectual property through digital rights management.
The solution allows for on-demand manufacturing of various underhood and cabin interior parts, reducing delivery time by up to 75%. Service providers can join Daimler's network by purchasing a 3DXpert license through their Omniplus 3D-Printing License eShop. The system currently works with 3D Systems' SLS 380 printer, with plans to expand to other polymer and metal printers.
This initiative aims to overcome supply chain bottlenecks and minimize vehicle downtime due to maintenance. The automotive additive manufacturing market is projected to grow from $2.9 billion in 2022 to $7.9 billion by 2027.
Systemic Bio, a 3D Systems (NYSE: DDD) company, has been selected as a Top 10 Finalist for the SLAS 2025 Innovation Award. The company's proprietary h-VIOS™ platform, which accelerates drug discovery using bioprinted tissues, earned this recognition at the SLAS International Conference and Exhibition.
Operating from a Houston-based ISO 7 clean room facility under a Quality Management System, Systemic Bio can produce thousands of tissue models that mimic human organ systems with high precision. The platform represents a significant advancement in preclinical testing, supporting collaborations with leading pharmaceutical companies.
CEO Taci Pereira emphasized the recognition's significance in highlighting their platform's transformative potential in pharmaceutical innovation. Systemic Bio will present "h-VIOS: A human-relevant drug discovery and development platform using bioprinted human tissues" at the SLAS Conference in San Diego on January 27, 2025. The winner announcement is scheduled for January 29, 2025.
3D Systems (NYSE:DDD) has announced its participation in the 27th Annual Needham Growth Conference scheduled for January 14, 2025. The company's President and CEO, Dr. Jeffrey Graves, will engage in a fireside chat at 11:45 a.m. Eastern Standard Time and conduct individual meetings with the company's leadership team throughout the day.
A live webcast of the conference presentation will be accessible through 3D Systems' Investor Relations page. The webcast link will become active shortly before the event begins and will be available for on-demand viewing approximately 24 hours after the event concludes, with -time access following the conference.
3D Systems (NYSE:DDD) has announced the sale of its Geomagic® software portfolio to Hexagon's Manufacturing Intelligence Division for $123 million. The transaction is expected to close in the first half of 2025. Following this strategic divestiture, 3D Systems will focus on its core software platforms: 3D Sprint®, 3DXpert®, and Oqton Industrial Manufacturing OS.
The company aims to sharpen its focus on software solutions that accelerate the adoption of 3D printing technologies in large-scale production environments. This strategic shift will emphasize leveraging AI and machine learning capabilities to enhance workflows, improve productivity, reduce costs, and enhance component quality in production settings.
3D Systems (NYSE:DDD) reported Q3 2024 financial results with revenue of $112.9 million, down 9% year-over-year. The decline was primarily due to weak printer sales, partially offset by 10% growth in consumables. Healthcare Solutions revenue grew 5% to $55.1 million. The company reported a net loss of $178.6 million, including $143.7 million from goodwill impairment. Q3 gross profit margin was 36.9%, down from 44.7% last year. The company updated its FY2024 guidance, expecting revenues between $440-450 million. Cash position stood at $190.0 million as of September 30, 2024.
3D Systems (NYSE:DDD) announced it will release its Q3 2024 financial results after market close on Tuesday, November 26, 2024, followed by a conference call on Wednesday, November 27. The company received a NYSE Notice on November 19 for non-compliance with listing requirements due to delayed filing of its Q3 Form 10-Q. While this notice doesn't immediately affect DDD's NYSE listing, the company has six months to regain compliance. 3D Systems expects to resolve this by filing the Form 10-Q on November 26, 2024.
3D Systems (NYSE:DDD) announced that Sauber Motorsports will enhance its manufacturing workflow with 10 new 3D printers - eight SLA 750 Dual and two PSLA 270 units. The implementation aims to accelerate wind tunnel testing and increase production capacity. The SLA 750 Dual, recognized as the fastest Stereolithography solution available, offers superior print size, speed, and accuracy. Sauber becomes the first Formula 1 team to adopt the new PSLA technology, which combines accuracy with speed. The partnership builds on a nearly two-decade relationship between the companies, supporting the growing automotive 3D printing market, which is projected to reach $7.9 billion by 2027.
3D Systems (NYSE:DDD) announced preliminary Q3 2024 revenue of approximately $112.9 million, representing a $10.9 million decrease from Q3 2023's $123.8 million. The decline was primarily due to macroeconomic factors affecting hardware systems sales. However, consumable materials revenue grew 10% year-over-year and 9% sequentially. The company's Personalized Healthcare business showed strong performance with nearly 20% growth. The company secured FDA clearances for multi-material jetted dentures and TOTAL ANKLE Patient-Matched Guides. The Q3 2024 Form 10-Q filing is delayed due to required interim valuation of goodwill and long-lived assets.